Could a decades-old arthritis drug protect dialysis patients' hearts and veins?

NCT ID NCT07762807

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether low-dose colchicine, an inexpensive anti-inflammatory drug, is safe and acceptable for people on hemodialysis. Researchers will give 100 dialysis patients colchicine for about 3 months, monitoring side effects and how many stick with it. The goal is to see if a larger trial is possible to test whether colchicine can reduce heart attacks and strokes and help dialysis access points last longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
colchicine 0.5 mg taken orally once daily for 3 months and 2 weeks
What this could lead to
If tolerated, colchicine could reduce heart attacks and strokes in dialysis patients and help their vascular access last longer, potentially improving survival and quality of life.
What could go wrong
This is a small feasibility study, not a large efficacy trial. Dialysis patients may not tolerate colchicine well, and any benefits remain unproven until larger trials are done.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLCHICINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Guy's and St Thomas' NHS Trust

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.